000			02084nam a22002057a 4500
001			D0001J000020
003			DOH
005			20210211113836.0
008			210211b ||||| |||| 00| 0 eng d
245	0	0	_aCost-effectiveness analysis of imidapril compared to metoprolol in the treatment of stage 1 essential hypertension among Filipino patients seen at the Philippine General Hospital / _cHe Wentian [two others]
520	3		_aOBJECTIVE: To evaluate the cost-effectiveness of imidapril versus metoprolol as monotherapy in Filipino patients with Stage 1 essential hypertension. STUDY DESIGN: Cost-effectiveness analysis from the perspective of the health care payer. METHOD: Medical records of 94 out-patients aged 40-70 years old, with Stage 1 essential hypertension and follow-up treatment of 3 months at the Philippine General Hospital were reviewed. Effectiveness of each drug was based on: 1) percentage of patients achieving target blood pressure (< 140 / 90 mmHg); and 2) mean reduction of systolic and diastolic blood pressure. Cost-effectiveness of each drug was evaluated using the criteria of cost-effectiveness ratio (CER) and the incremental cost-effectiveness ratio (ICER). RESULTS: The mean cost of treatment with metoprolol was significantly lower than imidapril. However, treatment with imidapril resulted in a statistically significantly better blood pressure control compared to metoprolol; 77 percent of those given imidapril achieved the target BP vs 56 percent for metoprolol (p=0.03). CER and the ICER showed that 3-months treatment with metoprolol is more cost-effective than the use of imidapril. CONCLUSION: Use of metoprolol over a 3-month period is more cost-effective than imidapril in the treatment of Filipino patients with Stage 1 essential hypertension.
580			_aIn: Acta Medica Philippina, 2006 vol. 40 (1) pages: 29-36
650		2	_aMetoprolol
650		2	_aHypertension _xtherapy
653			_aImidapril
700	1		_aWentian, He
700	1		_aJimeno, Cecilia A.
700	1		_aPanelo, Carlo Irwin A.
942			_cJA
999			_c2804 _d2804